## Background: Chronically hospitalized geriatric inpatients with schizophrenia are at particular risk for both tardive dyskinesia (td) and cognitive impairment but have been insufficiently studied in this regard. similarly, the relationship between td and cognitive impairment has not be adequately
A blessing in disguise: Resolution of tardive dyskinesia with development of cervical myelitis
β Scribed by Erle Chuen-Hian Lim; Einar P.V. Wilder-Smith; Raymond Chee-Seong Seet
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 72 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Tardive dyskinesia (TD), which is frequently seen in patients treated with dopamine receptor blocking agents, is difficult to manage. We report on a young Chinese man with bipolar disorder who developed TD after haloperidol treatment, involving the trunk, limbs, and orofacial area. TD persisted despite switching to atypical antipsychotic agents and treatment with valproate, benzodiazepines, and tetrabenazine. Resolution only occurred years later when he developed quadriplegia arising from infective myelitis of the cervical cord (C4β5). He had concomitant vertebral osteomyelitis, which was successfully treated with intravenous antibiotics. With intensive rehabilitation, he recovered the use of his limbs, but had no recurrence of TD. We attribute the resolution of orofacial dyskinesias with a cervical lesion to the interconnections between the orofacial area and cervical spine via the trigeminal nucleus (which has fibers descending as far caudally as C6), as well as to resetting of cortical maps. Β© 2005 Movement Disorder Society
π SIMILAR VOLUMES
Neuroleptic induced akathisia is a common and distressful extrapyramidal side effect of antipsychotic treatment. A significant proportion of the variability of its development has been left unexplained and has to be attributed to individual susceptibility. Since hereditary factors have been discusse
## Abstract Glucagonβlike peptideβ2 (GLPβ2) is a potent intestinotrophic growth factor that enhances repair of damaged intestinal tissue. However, its bioactivity is limited by dipeptidyl peptidase IV (DPIV)βmediated degradation. We hypothesized that DPIV^β/β^ mice would display an increased resist